Skip to content

Metabonomics and proteomics based on the longitudinal follow-up cohort using to construct and validate primary glaucoma diagnosis, progression, and prognosis models

Metabonomics and proteomics based on the longitudinal follow-up cohort using to construct and validate primary glaucoma diagnosis, progression, and prognosis models

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035747
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

proteomics
Gold Standard:PACG was diagnosed based on narrow anterior chamber angles with glaucomatous optic neuropathy and corresponding VF loss. VF loss was determined by including a cluster of three or more no

Sponsors

Eye, Ear, nose and throat Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old, which met the diagnostic criteria of POAG/PACG; 2. Glaucomatous optic nerve damage with corresponding visual field defect occurred in one or both eyes; 3. Priority was given to POAG/PACG patients with severe phenotype (binocular cup/plate ratio >=0.8).

Exclusion criteria

Exclusion criteria: 1. With other inherited eye diseases or hereditary diseases; 2. other diseases that seriously impair vision and visual field, including retinitis pigmentosa, diabetic retinopathy, wet-age related macular degeneration, pathological myopia and other diseases; 3. Secondary glaucoma or secondary intraocular pressure increased diseases were excluded, including glaucoma ciliary body syndrome, pigmentation glaucoma, stripping glaucoma, neovascular glaucoma, uveitis, blunt contusion of the eye, etc.Eliminate immune system diseases; 4. with no signs of glaucoma, no other inherited eye diseases or hereditary diseases in the control samples, excluding other diseases that seriously impair vision and visual field, including retinitis pigmentosa, diabetic retinopathy, wet-age related macular degeneration, pathological myopia, etc.; 5. Secondary glaucoma or secondary intraocular pressure increased diseases were excluded, including glaucoma ciliary body syndrome, pigmentation glaucoma, stripping glaucoma, neovascular glaucoma, uveitis, blunt contusion of the eye, etc.; 6. Eliminate immune system diseases.

Design outcomes

Primary

MeasureTime frame
metabonomics;proteomics;

Countries

China

Contacts

Public ContactLi Shengjie

Eye, Ear, nose and throat Hospital, Fudan University

lishengjie6363020@163.com+86 18317089693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026